CAJ | 학술논문

目的探讨Fms样酪氨酸激酶3(FLT3)表达对评估急性髓系白血病(AML)预后的意义.方法选取AML患者50例,其中核型正常的AML患者20例,核型异常的AML患者30例.分别于化疗前抽取骨髓3 ml,用PCR方法检测白血病细胞FLT3的表达情况.结果核型正常的AMLFLT3的表达率为5.0％,核型异常的AMLFLT3的表达率为26.7％.难治复发的AMLFLT3的表达率是33.3％,持续完全缓解的AMLFLT3的表达率是4.5％.FLT3的表达情况与骨髓中高白血病细胞所占比例和高外周血白细胞计数有关,与FAB亚型无关.有FLT3表达的AML患者无病生存(DFS)和总体生存(OS)时间短,无FLT3表达的AML患者DFS和OS时间长,二者差异有统计学意义(x2=4.17,P＜0.05).结论 FLT3是AML患者预后不好的因素,可以指导临床个体化治疗AML.
목적 탐토Fms양락안산격매3(FLT3)표체대평고급성수계백혈병(AML)예후적의의.방법 선취AML환자50례,기중핵형정상적AML환자20례,핵형이상적AML환자30례.분별우화료전추취골수3 ml,용PCR방법검측백혈병세포FLT3적표체정황.결과 핵형정상적AMLFLT3적표체솔위5.0％,핵형이상적AMLFLT3적표체솔위26.7％.난치복발적AMLFLT3적표체솔시33.3％,지속완전완해적AMLFLT3적표체솔시4.5％.FLT3적표체정황여골수중고백혈병세포소점비례화고외주혈백세포계수유관,여FAB아형무관.유FLT3표체적AML환자무병생존(DFS)화총체생존(OS)시간단,무FLT3표체적AML환자DFS화OS시간장,이자차이유통계학의의(x2=4.17,P＜0.05).결론 FLT3시AML환자예후불호적인소,가이지도림상개체화치료AML.
Objective To explore the clinical significance of fms-like tyrosine kinase3(FLT3) expression in evaluation prognosis of acute myeloid leukemia(AML) prognosis.Methods 50 patients with AML were selected.AML patients with normal karyotype were 20 cases,the abnormal karyotype were 30 cases.3ml bone marrow before themotherapy was aspirated respectively,and the FLT3 gene expression in leukemia cells was detected with polyenzyme chain react(PCR).Results The FLT3 expression rate in AML patients with normal karyotype was 5.0％,and was 26.7％ in AML patients with abnormal karyotype,33.3％ in AML patients with refractory-relapse,and 4.5％ in AML patients with continue remission.The FLT3 expression rate was related with high leukemia cells percentage in bone marrow and high blood cells count in peripheral blood,and was not related with Franch America British(FAB) classification.The free-disease survival(FDS) and overall survived(OS) was shorter in FLT3 expression AML patients than that in no FLT3 expression AML patients.There was a statistical significance between the former and the latter( x2 =4.17,P ＜0.05 ).Conclusion FLT3 was a kind of worse factor in AML patients prognosis,and could guide clinical individual treatment in AML.